Ahmed Mousa
Chief Executive Officer Vicore Pharma Holding
Ahmed Mousa, CEO of Vicore Pharma, brings a strong track record in corporate development, strategic partnerships, and pipeline advancement in the life sciences industry. At Vicore, he is leading efforts to pioneer novel treatments for idiopathic pulmonary fibrosis (IPF) through modulation of the AT2 receptor pathway. Prior to Vicore, Ahmed was Chief Business Officer & General Counsel at Pieris Pharmaceuticals, where he drove key collaborations and pipeline growth. He also brings legal expertise from Covington & Burling and Kirkland & Ellis, advising biopharma companies on strategic and regulatory matters.
Seminars
Thursday 21st August 2025
Promoting Tissue Regeneration Through Modulation of AT2 Receptor Pathway
11:30 am
- Harnessing the AT2 receptor pathway to drive lung tissue repair and counteract fibrotic remodeling in pulmonary diseases, a distinct mechanism from conventional antifibrotics
- Exploring the regenerative potential of C21, an AT2R agonist, to restore alveolar epithelial function and promote vascular integrity
- Advancing a new class of regenerative therapies by targeting endogenous repair pathways, with a focus on improving clinical outcomes through enhanced lung function, symptom relief, and disease modification.
Thursday 21st August 2025
Panel Discussion: Exploring the Feasibility and Future of Lung Regeneration in IPF: Challenges, Opportunities, and Emerging Therapies
2:00 pm
Panel Discussion Points:
- Is complete lung regeneration achievable, or is the primary goal to halt further tissue damage and improve function in IPF?
- What are the potential risks (e.g., tumorigenesis, stem cell activation) versus the promising benefits of regenerative therapies?
- Which biomarkers are crucial to track and validate the success of regenerative approaches in IPF?
- How can insights from tissue engineering, oncology, and other regenerative medicine areas inform and advance lung regeneration therapies for IPF?
- Which regenerative approaches are showing real potential for recovery versus those focusing on disease modification in the IPF treatment landscape?
